Cresco Labs (CRLBF) Asset Writedowns and Impairment (2020 - 2026)
Cresco Labs' (CRLBF) quarterly Asset Writedowns and Impairment came in at $741000.0 in Q1 2026, down 17.85% YoY from $902000.0 in Q1 2025, and down 99.21% on a QoQ basis from $93.5 million in Q4 2025.
Cresco Labs (CRLBF) Asset Writedowns and Impairment (2020 - 2026) Analysis & Trends
Cresco Labs (CRLBF) has 7 years of Asset Writedowns and Impairment data on file, last reported at $741000.0 in Q1 2026.
- Quarterly Asset Writedowns and Impairment fell 17.85% year-over-year to $741000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $104.9 million (up 3600.33% YoY) and the FY2025 annual result came in at $105.1 million, up 10410.1% from the prior year.
- Asset Writedowns and Impairment declined to $741000.0 in Q1 2026, from $93.5 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $139.4 million in Q4 2022 to a low of -$140.3 million in Q4 2023.
- A 5-year average of $15.2 million and a median of $902000.0 in 2022 frame the typical range for Asset Writedowns and Impairment.
- The widest YoY moves for Asset Writedowns and Impairment: up 23147.94% in 2023, down 200.66% in 2023.
- Tracing CRLBF's Asset Writedowns and Impairment over 5 years: stood at $139.4 million in 2022, then slumped by 200.66% to -$140.3 million in 2023, then soared by 99.06% to -$1.3 million in 2024, then jumped by 7181.14% to $93.5 million in 2025, then plunged by 99.21% to $741000.0 in 2026.
- The last three Asset Writedowns and Impairment figures came in at $741000.0 (Q1 2026), $93.5 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Cresco Labs | 295.09 Mn | 230.98 Mn | 86.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 741,000.00 |
| Mar 31, 2026 | 741,000.00 |
| Dec 31, 2025 | 93.47 Mn |
| Dec 31, 2025 | 93.47 Mn |
| Sep 30, 2025 | 2.37 Mn |
| Sep 30, 2025 | 2.37 Mn |
| Jun 30, 2025 | 8.36 Mn |
| Jun 30, 2025 | 8.36 Mn |
| Mar 31, 2025 | 902,000.00 |
| Mar 31, 2025 | 902,000.00 |
| Dec 31, 2024 | -1.32 Mn |
| Dec 31, 2024 | -1.32 Mn |
| Sep 30, 2024 | -57,000.00 |
| Sep 30, 2024 | -57,000.00 |
| Jun 30, 2024 | -2.52 Mn |
| Jun 30, 2024 | -2.52 Mn |
| Mar 31, 2024 | 4.90 Mn |
| Mar 31, 2024 | 4.90 Mn |
| Dec 31, 2023 | -140.29 Mn |
| Dec 31, 2023 | -140.29 Mn |